A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer.Scot Ebbinghaus, José Baselga, Charles Swanton et al.|Journal of Clinical Oncology|2011Cited by 5
334 Gene Expression Analysis of Human Sarcoma Tissues to Explore Clinical Outcomes of mTOR Inhibition with Ridaforolimus: Correlative Science From the Phase III SUCCEED Trial Testing Maintenance Therapy for Metastatic DiseaseT. Zhang, Jean‐Yves Blay, Scot Ebbinghaus et al.|European Journal of Cancer|2012Cited by 0